Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 20, 2016. The report details a blocklisting application submitted to the Financial Conduct Authority and the London Stock Exchange Plc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notice regarding share issuance rather than a financial performance report.
Material Changes
The material change reported is the reservation of 4,000,000 Ordinary shares of 25p each for admission to the Official List. These shares are reserved under block listings for future issuance pursuant to employee share schemes.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The only unusual item noted is the specific allocation of shares for the GlaxoSmithKline Share Option Plan (2,000,000 shares) and the GlaxoSmithKline plc Sharesave plan 2012 (2,000,000 shares). Upon issuance, these shares will rank pari passu with existing ordinary shares.
Investor Verification Points
- Confirmation of the admission of 4,000,000 Ordinary shares to the Official List.
- Verification of the split between the Share Option Plan and the Sharesave plan 2012.
- Confirmation that the new shares rank pari passu with existing ordinary shares.